Prevalence and recovery of adrenal insufficiency in steroid-dependent asthma patients receiving biologic therapy

Alexandra M. Nanzer, Aqib Chowdhury, Asma Raheem, Cris Roxas, Mariana Fernandes, Louise Thomson, Linda Green, Jaideep Dhariwal, Grainne D’Ancona, Brian D. Kent, Philip A. Kelly and David J. Jackson

Affiliations: 1Guy’s and St Thomas’ NHS Foundation Trust, Thoracic Medicine, Guy’s Severe Asthma Service, London, UK. 2King’s College London, London, UK. 3King’s College Hospital NHS Foundation Trust, Dept of Acute Medicine, London, UK.

Correspondence: Alexandra Nanzer, Guy’s and St Thomas’ Hospitals, Guy’s Severe Asthma Service, Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK. E-mail: alexandra.nanzerkelly@gstt.nhs.uk

To the Editor:

Asthma is a complex and heterogeneous inflammatory disease of the airways. Regular inhaled corticosteroid (ICS) therapy suppresses airway inflammation and treats asthma symptoms sufficiently in most patients. However, a small, but significant, proportion of patients with severe disease suffer from persistent daily symptoms and are reliant on oral corticosteroids (OCS), for short-term control in acute exacerbations, or as long-term maintenance therapy [1].

Adrenal insufficiency is common in previously steroid-dependent asthma patients. Morning serum cortisol is a valid and important first line test which can indicate adrenal insufficiency and can guide who might need dynamic testing. http://bit.ly/2IVGNfI


This single-page version can be shared freely online.